Stephen A. Metcalf

Stephen A. Metcalf

Auto-generated profile, based on publicly available information

Stephen A. Metcalf

Center for Technology and Behavioral Health Geisel School of Medicine at Dartmouth Lebanon, NH United States

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Brain, Behavior, and Immunity
Verified
Journal Article
Open access
SMStephen A. Metcalf
Stephen A. Metcalf
PJPeter B. Jones
Peter B. Jones
TNTanja Nordstrom
Tanja Nordstrom
MTMarkku Timonen
Markku Timonen
PMPirjo Mäki
Pirjo Mäki
GKGolam M. Khandaker
Golam M. Khandaker
Meta-analyses of cross-sectional studies confirm an increase in circulating inflammatory markers during acute psychosis. Longitudinal studies are scarce but are needed to understand whether elevated inflammatory markers are a cause or consequence of illness. We report a longitudinal study of serum C-reactive protein (CRP) in adolescence and subsequent risk of schizophrenia and related psychoses in adulthood in the Northern Finland Birth Cohort 1986. Serum high-sensitivity CRP was measured at age 15/16 years in 6362 participants. ICD-10 diagnoses of schizophrenia and related psychoses were obtained from centralised hospital inpatient and outpatient registers up to age 27 years. Logistic regression calculated odds ratios (ORs) for psychotic outcomes associated with baseline CRP levels analysed as both continuous and categorical variables using American Heart Association criteria. Age, sex, body mass index, maternal education, smoking, and alcohol use were included as potential confounders. By age 27years, 88 cases of non-affective psychosis (1.38%), of which 22 were schizophrenia (0.35%), were identified. Adolescent CRP was associated with subsequent schizophrenia. The adjusted OR for schizophrenia by age 27yearsfor each standard deviation (SD) increase in CRP levels at age 15/16yearswas 1.25 (95% CI, 1.07-1.46), which was consistent with a linear, dose-response relationship (P-value for quadratic term 0.23). Using CRP as a categorical variable, those with high (>3mg/L) compared with low (<1mg/L) CRP levels at baseline were more likely to develop schizophrenia; adjusted OR 4.25 (95% CI, 1.30-13.93). There was some indication that higher CRP was associated with earlier onset of schizophrenia (rs=-0.40; P=0.07). A longitudinal association between adolescent CRP levels and adult schizophrenia diagnosis indicates a potentially important role of inflammation in the pathogenesis of the illness, although the findings, based on a small number of cases, need to be interpreted with caution and require replication in other samples.

1 December 2019 in International Journal of Drug Policy
Verified
Journal Article
Closed access
SBSarah Bessen
Sarah Bessen
SMStephen A. Metcalf
Stephen A. Metcalf
ESElizabeth C. Saunders
Elizabeth C. Saunders
SMSarah K. Moore
Sarah K. Moore
AMAndrea Meier
Andrea Meier
LMLisa A. Marsch
Lisa A. Marsch

1 February 2018 in Behaviour Research and Therapy
Verified
Journal Article
Closed access
IEIan W. Eisenberg
Ian W. Eisenberg
PBPatrick G. Bissett
Patrick G. Bissett
JCJessica R. Canning
Jessica R. Canning
JDJesse Dallery
Jesse Dallery
AEA. Zeynep Enkavi
A. Zeynep Enkavi
RPRussell A. Poldrack
Russell A. Poldrack

21 January 2020 in Journal of Substance Abuse Treatment
Verified
Journal Article
Closed access
ESElizabeth C. Saunders
Elizabeth C. Saunders
SMSarah K. Moore
Sarah K. Moore
OWOlivia Walsh
Olivia Walsh
SMStephen A. Metcalf
Stephen A. Metcalf
ABAlan J. Budney
Alan J. Budney
LMLisa A. Marsch
Lisa A. Marsch

1 November 2019 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
ESElizabeth Saunders
Elizabeth Saunders
SMStephen A. Metcalf
Stephen A. Metcalf
OWOlivia Walsh
Olivia Walsh
SMSarah K. Moore
Sarah K. Moore
AMAndrea Meier
Andrea Meier
LMLisa A. Marsch
Lisa A. Marsch

28 May 2021 in Schizophrenia
Verified
Journal Article
Open access
PDF file
EOEmanuele F. Osimo
Emanuele F. Osimo
LBLuke Baxter
Luke Baxter
JSJan Stochl
Jan Stochl
BPBenjamin I. Perry
Benjamin I. Perry
SMStephen A. Metcalf
Stephen A. Metcalf
GKGolam M. Khandaker
Golam M. Khandaker
Meta-analyses of cross-sectional studies suggest that patients with psychosis have higher circulating levels of C-reactive protein (CRP) compared with healthy controls; however, cause and effect is unclear. We examined the prospective association between CRP levels and subsequent risk of developing a psychotic disorder by conducting a systematic review and meta-analysis of population-based cohort studies. Databases were searched for prospective studies of CRP and psychosis. We obtained unpublished results, including adjustment for age, sex, body mass index, smoking, alcohol use, and socioeconomic status and suspected infection (CRP > 10 mg/L). Based on random effect meta-analysis of 89,792 participants (494 incident cases of psychosis at follow-up), the pooled odds ratio (OR) for psychosis for participants with high (>3 mg/L), as compared to low (≤3 mg/L) CRP levels at baseline was 1.50 (95% confidence interval [CI], 1.09–2.07). Evidence for this association remained after adjusting for potential confounders (adjusted OR [aOR] = 1.31; 95% CI, 1.03–1.66). After excluding participants with suspected infection, the OR for psychosis was 1.36 (95% CI, 1.06–1.74), but the association attenuated after controlling for confounders (aOR = 1.23; 95% CI, 0.95–1.60). Using CRP as a continuous variable, the pooled OR for psychosis per standard deviation increase in log(CRP) was 1.11 (95% CI, 0.93–1.34), and this association further attenuated after controlling for confounders (aOR = 1.07; 95% CI, 0.90–1.27) and excluding participants with suspected infection (aOR = 1.07; 95% CI, 0.92–1.24). There was no association using CRP as a categorical variable (low, medium or high). While we provide some evidence of a longitudinal association between high CRP (>3 mg/L) and psychosis, larger studies are required to enable definitive conclusions.